GlassScriptPhysician profile
Sana Akbar
NPI 1922448604
$2,716.54
in general payments reported to CMS, 2019-2025
23 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.60 · 2021: $1,067 · 2022: $1,062 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.48 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $673.93 | 2021-2025 | Ozempic |
| Lilly USA, LLC | $346.62 | 2020-2025 | Zepbound, Mounjaro |
| Insulet Corporation | $271.98 | 2021-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $193.71 | 2022-2025 | Recorlev |
| Amneal Pharmaceuticals LLC | $165.71 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $160.97 | 2021-2022 | |
| Amgen INC. | $108.71 | 2021-2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $101.68 | 2022-2025 | |
| Antares Pharma, INC. | $94.95 | 2021-2025 | Xyosted |
| Abbott Laboratories | $76.57 | 2021-2025 | Freestyle Libre |
| Medtronic, INC. | $68.90 | 2021-2025 | Minimed 780g |
| Mannkind Corporation | $65.23 | 2021 | |
| Tandem Diabetes Care, INC. | $61.71 | 2021-2022 | |
| Corcept Therapeutics | $56.34 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $52.20 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $50.06 | 2021-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $34.90 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $33.24 | 2025 | Flector, Licart, Tirosint |
| Acerus Pharmaceuticals Corporation | $27.70 | 2021 | |
| Becton, Dickinson and Company | $21.76 | 2021 | |
| Abbvie INC. | $18.09 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.93 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.